Revenue grew 16% year-over-year in Q2 2026, with EBIT more than doubling and gross margin rising to 70%. Growth was broad-based, though longer prescription lead times in the U.S. and higher component costs are expected to impact margins. Strong cash flow enabled a SEK 53 million dividend.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.